Loading
People with Lynch syndrome have a very high lifetime cancer risk from a predictable set of mutations. Vaccinate them against those shared mutations before cancer appears.
Mismatch repair deficiency produces recurrent frameshift neoantigens shared across Lynch-associated tumours, and pilot vaccines have shown immunogenicity in carriers and in mice reduced tumour incidence. The proposal is to take a multi-epitope frameshift vaccine (mRNA or viral vector, possibly with a checkpoint-sparing adjuvant) into a randomised prevention trial in carriers with a surrogate endpoint of adenoma and early-cancer incidence at colonoscopy, positioning it as the first preventive cancer vaccine registration for a hereditary syndrome.
Because Lynch syndrome tumours make the same abnormal proteins in almost every patient, a single vaccine could in principle be given to carriers before cancer develops. This small trial showed the concept is safe and immunogenic; whether it prevents cancer requires the randomised trials now being planned.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Cancer interception vaccines for high-risk carriers, First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers, National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Neoantigen.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Prevention we already have is not deployed.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, Prevention we already have is not deployed.
Shares Neoantigen, Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).